Dupilumab vs placebo was linked to improved health-related quality of life and respiratory symptoms in patients with COPD and T2 inflammation.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback